The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Statins Decrease Toll-Like Receptor 4 Expression and Downstream Signaling in Human CD14 + Monocytes
Open accessAbstract
Objective— Anti-inflammatory effects of statins contribute to their clinical benefit. Molecular mechanisms underlying these effects have not been well explored. Because statins attenuate lipopolysaccharide (LPS) responsiveness, we hypothesized that part of the pleiotropic effects are mediated through innate immunity. Methods and Results— Toll-like receptor (TLR) 4 expression and downstream signaling in CD14 + monocytes after incubation with simvastatin and atorvastatin were quantified via flow-cytometry, quantitative RT-PCR, kinase assay, and enzyme-linked immunosorbent assay. Incubation with intermediates/ inhibitors of the mevalonate pathway was used to identify the mode of statin action. Statin incubation resulted in a dose-dependent reduction of TLR4 expression (53±7.6% reduction compared with untreated monocytes; P <0.005), transcript levels (68±6.3%; P <0.002), decreased IRAK phosphorylation (37±8.3%; P <0.05), and LPS-induced IL-6, IL-12, tumor necrosis factor (TNF)-α, and B7-1 expression ( P <0.05). Four weeks of treatment with atorvastatin significantly reduced TLR4 expression on circulating CD14 + monocytes by 36.2±4.2% ( P <0.05). Effects of statins were reversed by mevalonate ( P =0.57). Incubation with specific inhibitors of geranylgeranyltransferase (54±4.3%), farnesyltransferase (57±5.1%), or with clostridium-difficile toxin B (58±6.1%, P <0.01) imitated the statin effects. Whereas wortmannin and LY294002 inhibited the statin effect ( P =0.27), incubation with a specific RhoA kinase inhibitor had no effect ( P =0.57). Conclusions— Statins influence TLR4 expression and signaling via inhibition of protein geranylgeranylation and farnesylation. These observations imply interactions with innate immunity as one pleiotropic mechanism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A similar effect was also observed in human CD14+ monocytes treated with atorvastatin, whereby TLR 4 expression was significantly down-regulated (Methe et al., 2005).”
From Atorvastatin Reduces the Survival of Candida albicans-Infected BALB/c Mice (2015) · cites this paper as Methe et al., 2005
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Akira, S., & Takeda, K. (2004) · Nature reviews. Immunology · doi:10.1038/nri1391 · Cited by 8,312
Defective LPS Signaling in C3H/HeJ and C57BL/10ScCr Mice: Mutations in Tlr4 Gene
Poltorak, A., He, X., Smirnova, I., Liu, M.-Y., Huffel, C. V., Du, X., Birdwell, D., Alejos, E., Silva, M., Galanos, C., et al. (1998) · Science · doi:10.1126/science.282.5396.2085 · Cited by 7,631
A human homologue of the Drosophila Toll protein signals activation of adaptive immunity
Medzhitov, R., Preston-Hurlburt, P., & Janeway, C. A. J. (1997) · Nature · doi:10.1038/41131 · Cited by 6,137
Toll-like receptors control activation of adaptive immune responses
Schnare, M., Barton, G. M., Czopik, A. K., Takeda, K., Akira, S., & Medzhitov, R. M. (2001) · Nature Immunology · doi:10.1038/ni712 · Cited by 1,364
Pleiotropic Effects of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors
Takemoto, M., & Liao, J. K. (2001) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/hq1101.098486 · Cited by 1,274
Zarember, K. A., & Godowski, P. J. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.2.554 · Cited by 1,251
Edfeldt, K., Swedenborg, J., Hansson, G. K., & Yan, Z.-Q. (2002) · PubMed · Cited by 847
Expression of Toll-Like Receptors in Human Atherosclerotic Lesions
Edfeldt, K., Swedenborg, J., Hansson, G. K., & Yan, Z.-Q. (2002) · Circulation · doi:10.1161/circ.105.10.1158 · Cited by 706
Abreu, M. T., Vora, P., Faure, E., Thomas, L. S., Arnold, E. T., & Arditi, M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.3.1609 · Cited by 681
Xu, X.-O. H., Shah, P. K., Faure, E., Equils, O., Thomas, L. S., Fishbein, M. C., Luthringer, D., Xu, X., Rajavashisth, T. B., Yano, J., et al. (2001) · Circulation · doi:10.1161/hc5001.100631 · Cited by 676
Toll-like receptor 2–mediated NF-κB activation requires a Rac1-dependent pathway
Arbibe, L., Mira, J. P., Teusch, N. E., Kline, L., Guha, M., Mackman, N., Godowski, P. J., Ulevitch, R. J., & Knaus, U. G. (2000) · Nature Immunology · doi:10.1038/82797 · Cited by 664
PI3K and negative regulation of TLR signaling
Fukao, T., & Koyasu, S. (2003) · Trends in Immunology · doi:10.1016/s1471-4906(03)00139-x · Cited by 619
Involvement of Reactive Oxygen Species in Toll-Like Receptor 4-Dependent Activation of NF-κB
Asehnoune, K., Strassheim, D., Mitra, S., Kim, J. Y., & Abraham, E. H. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.4.2522 · Cited by 566
Self-citationFaure, E., Thomas, L. S., Xu, H., Medvedev, A. E., Equils, O., & Arditi, M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.3.2018 · Cited by 443
Miller, Y. I., Viriyakosol, S., Binder, C. J., Feramisco, J. R., Kirkland, T. N., & Witztum, J. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209634200 · Cited by 398
Ortego, M., Bustos, C., Hernández-Presa, M. Á., Tuñón, J., Díaz, C., Hernández, G., & Egido, J. (1999) · Atherosclerosis · doi:10.1016/s0021-9150(99)00193-8 · Cited by 339
Kita, T., Brown, M. S., & Goldstein, J. L. (1980) · Journal of Clinical Investigation · doi:10.1172/jci109938 · Cited by 306
In Vivo Anti-Inflammatory Effect of Statins Is Mediated by Nonsterol Mevalonate Products
Diomede, L., Albani, D., Sottocorno, M., Donati, M. B., Bianchi, M., Fruscella, P., & Salmona, M. (2001) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/hq0801.094222 · Cited by 246
In Vivo Evidence for a Role of Toll-Like Receptor 4 in the Development of Intimal Lesions
Vink, A., Schoneveld, A. H., van der Meer, J. J., van Middelaar, B. J., Sluijter, J. P. G., Smeets, M. B., Quax, P. H. A., Lim, S. K., Borst, C., Pasterkamp, G., et al. (2002) · Circulation · doi:10.1161/01.cir.0000032146.75113.ee · Cited by 243
Boekholdt, S. M., Agema, W. R. P., Peters, R. J. G., Zwinderman, A. H., van der Wall, E. E., Reitsma, P. H., Kastelein, J. J. P., & Jukema, J. W. (2003) · Circulation · doi:10.1161/01.cir.0000068311.40161.28 · Cited by 224
TLR4-mediated inflammatory activation of human coronary artery endothelial cells by LPS
Zeuke, S. (2002) · Cardiovascular Research · doi:10.1016/s0008-6363(02)00512-6 · Cited by 212
Erridge, C., Stewart, J. M., & Poxton, I. R. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022078 · Cited by 192
Differential inhibitory effects of lovastatin on protein isoprenylation and sterol synthesis.
Sinensky, M. S., Beck, L. A., Leonard, S. S., & Evans, R. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)45464-0 · Cited by 172
Zelvyté, I., Dominaitiene, R., Crisby, M., & Janciauskiene, S. M. (2002) · Pharmacological Research · doi:10.1006/phrs.2001.0922 · Cited by 152
Weis, M., Pehlivanli, S., Meiser, B. M., & von Scheidt, W. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01430-9 · Cited by 133
Self-citationLow-Level Endotoxin Induces Potent Inflammatory Activation of Human Blood Vessels
Rice, J. B., Stoll, L. L., Li, W.-G., Denning, G. M., Weydert, J. A., Charipar, E. M., Richenbacher, W. E., Miller, F. J., & Weintraub, N. L. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000081741.38087.f9 · Cited by 121
Phagocytosis, Innate Immunity, and Host–Pathogen Specificity
Henneke, P., & Golenbock, D. T. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031256 · Cited by 89
Neurauter, G., Wirleitner, B., Laich, A., Schennach, H., WEISS, G., & Fuchs, D. (2003) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.2003.02021.x · Cited by 85
Netea, M. G., Hijmans, A., van Wissen, S., Smilde, T. J., Trip, M. D., Kullberg, B. J., de Boo, T., van der Meer, J. W. M., Kastelein, J. J. P., & Stalenhorf, A. F. H. (2004) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2004.01303.x · Cited by 66
Patel, T. R., & Corbett, S. (2003) · Surgery · doi:10.1067/msy.2003.241 · Cited by 15
Cited by
Sorted by citations
Kell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
Koushki, K., Shahbaz, S. K., Mashayekhi, K., Sadeghi, M., Zayeri, Z. D., Taba, M. Y., Banach, M., Al-Rasadi, K., Johnston, T. P., & Sahebkar, A. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-020-08791-9 · Cited by 382
Gao, W., Xiong, Y., Li, Q., & Yang, H. Y. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00508 · Cited by 372
Targeting inflammation in metabolic syndrome
Welty, F. K., Alfaddagh, A., & Elajami, T. K. (2016) · Translational Research · doi:10.1016/j.trsl.2015.06.017 · Cited by 287
Toll-like Receptor Status in Obesity and Metabolic Syndrome: A Translational Perspective
Jialal, I., Kaur, H., & Devaraj, S. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3092 · Cited by 290
Metadata
- Authors
- Methe, H., Kim, J.-O., Kofler, S., Nabauer, M., & Weis, M.
- Affiliations
- Ludwig-Maximilians-Universität München (DE)
- From the Department of Cardiology, Ludwig-Maximilians-University, Munich, Germany.
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 2005-07
- Volume
- 25
- Issue
- 7
- Pages
- 1439-1445
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W2143835519
- Cited by
- 172
- References
- 30
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 2 · 2023: 1 · 2022: 4 · 2021: 8 · 2020: 8 · 2019: 1 · 2018: 5 · 2017: 4 · 2016: 5 · 2015: 11 · 2014: 10 · 2013: 11 · 2012: 18
- FWCI
- 4.11
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Arteriosclerosis Thrombosis and Vascular Biology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- statins, simvastatin, atorvastatin, TLR4, CD14+ monocytes, innate immunity, lipopolysaccharide, mevalonate pathway, geranylgeranylation, farnesylation, geranylgeranyltransferase inhibitors, farnesyltransferase inhibitors, Clostridium difficile toxin B, anti-inflammatory activity, cytokine expression
- MeSH terms
- Atorvastatin, Phosphoinositide-3 Kinase Inhibitors, Adult, Bacterial Proteins, Bacterial Toxins, Cells, Cultured, Drug Interactions, Female, Heptanoic Acids, Humans, Lipopolysaccharides, Male, Middle Aged, Monocytes, Protein Kinases, Pyrroles, RNA, Messenger, Signal Transduction, Gene Expression, Cytokines, Protein Prenylation, B7-1 Antigen, Lipopolysaccharide Receptors, Hydroxymethylglutaryl-CoA Reductase Inhibitors, 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine, Phosphatidylinositol 3-Kinases, Protein Kinase Inhibitors, Toll-Like Receptor 4, Interleukin-1 Receptor-Associated Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
